CR9379A - Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq - Google Patents
Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fqInfo
- Publication number
- CR9379A CR9379A CR9379A CR9379A CR9379A CR 9379 A CR9379 A CR 9379A CR 9379 A CR9379 A CR 9379A CR 9379 A CR9379 A CR 9379A CR 9379 A CR9379 A CR 9379A
- Authority
- CR
- Costa Rica
- Prior art keywords
- orphanine
- nociceptine
- partials
- receiver
- complete
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
La presente invencion describe analogos de peptido de nociceptina/orfanina FQ, composiciones de los mismos, y su uso en el tratamiento de trastornos y disfunciones relacionadas con la activacion o bloqueo de receptores NOP.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000003A ITFE20050003A1 (it) | 2005-02-15 | 2005-02-15 | Agonisti pieni e parziali ed antagonisti del recettore per nocicettina/orfanina fq ad elevata potenza. |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9379A true CR9379A (es) | 2008-04-25 |
Family
ID=36685750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9379A CR9379A (es) | 2005-02-15 | 2007-09-13 | Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq |
Country Status (29)
Country | Link |
---|---|
US (1) | US8227414B2 (es) |
EP (1) | EP1851241B1 (es) |
JP (1) | JP5281292B2 (es) |
KR (1) | KR101294895B1 (es) |
CN (2) | CN101128482A (es) |
AU (1) | AU2006215639B2 (es) |
BR (1) | BRPI0606998B8 (es) |
CA (1) | CA2598121C (es) |
CR (1) | CR9379A (es) |
CU (1) | CU23823A3 (es) |
CY (1) | CY1116456T1 (es) |
DK (1) | DK1851241T3 (es) |
EA (1) | EA011325B1 (es) |
ES (1) | ES2541308T3 (es) |
HR (1) | HRP20150731T1 (es) |
HU (1) | HUE025000T2 (es) |
IL (1) | IL185235A (es) |
IT (1) | ITFE20050003A1 (es) |
MA (1) | MA29288B1 (es) |
MX (1) | MX2007009523A (es) |
NI (1) | NI200700205A (es) |
NO (1) | NO341856B1 (es) |
PL (1) | PL1851241T3 (es) |
PT (1) | PT1851241E (es) |
RS (1) | RS54095B1 (es) |
SI (1) | SI1851241T1 (es) |
UA (1) | UA91844C2 (es) |
WO (1) | WO2006087340A2 (es) |
ZA (1) | ZA200707714B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITNA20090026A1 (it) * | 2009-05-14 | 2010-11-15 | Agostino Bruno D | Agonisti del recettore nop e loro usi terapeutici |
CN112730849B (zh) * | 2021-01-14 | 2023-03-10 | 山西医科大学第二医院 | 内源性孤啡肽作为糖尿病合并无症状性心肌缺血的血清生物标志物的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003237119A1 (en) * | 2002-04-29 | 2003-11-17 | Euro-Celtique S.A. | Conformationally constrained peptides that bind the orl-1 receptor |
ITMI20022022A1 (it) * | 2002-09-24 | 2004-03-25 | Girolamo Calo' | Analoghi di nocicettina. |
ITMI20031349A1 (it) * | 2003-07-01 | 2005-01-02 | Ufpeptides S R L | Antagonisti del recettore nop e loro usi terapeutici. |
CN1634980A (zh) * | 2004-10-10 | 2005-07-06 | 兰州大学 | 孤啡肽的类似物 |
-
2005
- 2005-02-15 IT IT000003A patent/ITFE20050003A1/it unknown
-
2006
- 2006-02-15 PT PT67082859T patent/PT1851241E/pt unknown
- 2006-02-15 JP JP2007554583A patent/JP5281292B2/ja not_active Expired - Fee Related
- 2006-02-15 WO PCT/EP2006/050958 patent/WO2006087340A2/en active Application Filing
- 2006-02-15 KR KR1020077018487A patent/KR101294895B1/ko active IP Right Grant
- 2006-02-15 CA CA2598121A patent/CA2598121C/en not_active Expired - Fee Related
- 2006-02-15 UA UAA200709286A patent/UA91844C2/ru unknown
- 2006-02-15 RS RS20150443A patent/RS54095B1/en unknown
- 2006-02-15 CN CNA2006800049929A patent/CN101128482A/zh active Pending
- 2006-02-15 CN CN201510080020.9A patent/CN104689293A/zh active Pending
- 2006-02-15 US US11/884,241 patent/US8227414B2/en active Active
- 2006-02-15 HU HUE06708285A patent/HUE025000T2/en unknown
- 2006-02-15 DK DK06708285.9T patent/DK1851241T3/en active
- 2006-02-15 EA EA200701732A patent/EA011325B1/ru not_active IP Right Cessation
- 2006-02-15 MX MX2007009523A patent/MX2007009523A/es active IP Right Grant
- 2006-02-15 PL PL06708285T patent/PL1851241T3/pl unknown
- 2006-02-15 EP EP06708285.9A patent/EP1851241B1/en active Active
- 2006-02-15 ES ES06708285.9T patent/ES2541308T3/es active Active
- 2006-02-15 BR BRPI0606998A patent/BRPI0606998B8/pt not_active IP Right Cessation
- 2006-02-15 AU AU2006215639A patent/AU2006215639B2/en not_active Ceased
- 2006-02-15 SI SI200631947T patent/SI1851241T1/sl unknown
-
2007
- 2007-08-09 NI NI200700205A patent/NI200700205A/es unknown
- 2007-08-13 CU CU20070195A patent/CU23823A3/es active IP Right Grant
- 2007-08-13 IL IL185235A patent/IL185235A/en active IP Right Grant
- 2007-08-31 MA MA30190A patent/MA29288B1/fr unknown
- 2007-09-07 ZA ZA200707714A patent/ZA200707714B/xx unknown
- 2007-09-13 CR CR9379A patent/CR9379A/es not_active Application Discontinuation
- 2007-09-14 NO NO20074702A patent/NO341856B1/no not_active IP Right Cessation
-
2015
- 2015-07-06 HR HRP20150731TT patent/HRP20150731T1/hr unknown
- 2015-07-06 CY CY20151100579T patent/CY1116456T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
DE602007012072D1 (de) | Orantagonisten | |
CO6361994A2 (es) | Antagonistas del receptor de orexina de isonicotinamida | |
CY1110882T1 (el) | Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης | |
CY1113798T1 (el) | Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης | |
CR11042A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
SV2011003891A (es) | Antagonistas de los receptores tipo toll 3 | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
DK1791571T3 (da) | Radiofluorinerede peptider | |
CR11562A (es) | Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina | |
DE602007004999D1 (de) | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten | |
ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
CL2004000449A1 (es) | Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en | |
ATE429428T1 (de) | Indanderivate als antagonisten des mch-rezeptors | |
ATE474834T1 (de) | Als agonisten des gpr38-rezeptors geeignete biarylverbindungen | |
CL2009000119A1 (es) | Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer. | |
ATE538123T1 (de) | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors | |
ATE519498T1 (de) | Kombination aus somatostatin-analoga unterschiedlicher selektivität für humane somatostatin-rezeptor-subtypen | |
CL2008003602A1 (es) | Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos. | |
CL2008000091A1 (es) | Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria. | |
CR9379A (es) | Agonistas y antagonistas completos y parciales altamente potentes del receptor nociceptina/orfanina fq | |
UY31420A1 (es) | Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina | |
EA200802104A1 (ru) | Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств | |
PA8637801A1 (es) | Metabolitos de indolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR069026A1 (es) | Arilindenopirimidinas y su uso como antagonistas de los receptores de adenosina a₂a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |